44 Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.68M Sell
44,227
-13,853
-24% -$808K 0.94% 27
2025
Q4
$3.13M Sell
58,080
-8,482
-13% -$408K 1.05% 16
2025
Q3
$3M Buy
66,562
+9,257
+16% +$432K 1.02% 19
2025
Q2
$2.65M Sell
57,305
-2,686
-4% -$132K 0.94% 26
2025
Q1
$3.66M Sell
59,991
-1,059
-2% -$61.7K 1.37% 8
2024
Q4
$3.45M Sell
61,050
-2,235
-4% -$125K 1.33% 8
2024
Q3
$3.36M Buy
+63,285
New +$2.97M 1.18% 11
2023
Q2
$203K Sell
3,176
-10
-0.3% -$671 0.07% 164
2023
Q1
$221K Hold
3,186
0.07% 165
2022
Q4
$229K Buy
3,186
+20
+0.6% +$1.51K 0.08% 164
2022
Q3
$225K Hold
3,166
0.09% 153
2022
Q2
$244K Buy
3,166
+33
+1% +$2.51K 0.09% 149
2022
Q1
$229K Buy
+3,133
New +$210K 0.08% 157
2021
Q4
Sell
-29,142
Closed -$1.72M 183
2021
Q3
$1.72M Sell
29,142
-592
-2% -$39K 0.66% 44
2021
Q2
$1.99M Sell
29,734
-2,026
-6% -$132K 0.76% 35
2021
Q1
$2M Buy
31,760
+299
+1% +$18.6K 0.84% 33
2020
Q4
$1.95M Buy
+31,461
New +$1.93M 0.89% 30

Other funds holding BMY

44 Wealth Management's BMY Position: Q1 2026 in Review

44 Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 24% in Q1 2026, selling an estimated $808K and leaving 44,227 shares worth $2.68M. The position accounts for 0.94% of the portfolio, ranked #27.

44 Wealth Management first reported a position in BMY in Q4 2020 and has held it in 17 quarters since. The position peaked at $3.66M in Q1 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • 44 Wealth Management held 44,227 shares of Bristol-Myers Squibb worth $2.68M as of Q1 2026.
  • 44 Wealth Management sold 13,853 Bristol-Myers Squibb shares in Q1 2026, an estimated $808K.
  • Bristol-Myers Squibb made up 0.94% of 44 Wealth Management's portfolio in Q1 2026, its #27 holding.
  • 44 Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 17 quarters since.
  • 44 Wealth Management's Bristol-Myers Squibb position peaked at $3.66M in Q1 2025.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on 44 Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.